Needham & Company LLC Raises Definium Therapeutics (NASDAQ:DFTX) Price Target to $50.00

Definium Therapeutics (NASDAQ:DFTX) had its target price increased by equities researchers at Needham & Company LLC from $38.00 to $50.00 in a report released on Tuesday. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price target suggests a potential upside of 36.35% from the stock’s current price.

Several other research firms also recently issued reports on DFTX. Royal Bank Of Canada reiterated an “outperform” rating on shares of Definium Therapeutics in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a report on Tuesday, April 21st. Citigroup reaffirmed a “buy” rating on shares of Definium Therapeutics in a research report on Monday. Oppenheimer set a $60.00 price target on shares of Definium Therapeutics and gave the stock an “outperform” rating in a research note on Monday. Finally, Leerink Partners set a $52.00 price target on shares of Definium Therapeutics and gave the stock an “outperform” rating in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Definium Therapeutics has a consensus rating of “Buy” and an average price target of $44.54.

Definium Therapeutics Stock Performance

NASDAQ:DFTX opened at $36.67 on Tuesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69. The stock has a market capitalization of $3.66 billion, a P/E ratio of -14.73 and a beta of 2.37. The company has a 50 day moving average price of $22.98 and a 200 day moving average price of $18.58. Definium Therapeutics has a fifty-two week low of $6.34 and a fifty-two week high of $39.16.

Definium Therapeutics (NASDAQ:DFTX) last announced its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). Equities research analysts forecast that Definium Therapeutics will post -2.3 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Fifth Third Bancorp increased its holdings in Definium Therapeutics by 5,593.2% during the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after purchasing an additional 3,300 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after buying an additional 2,003 shares during the period. BNP Paribas Financial Markets grew its position in shares of Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after buying an additional 3,020 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new position in shares of Definium Therapeutics during the fourth quarter worth about $117,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Definium Therapeutics during the third quarter worth approximately $107,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Phase 3 Emerge data for DT120 were positive, with the study meeting the primary endpoint and all key secondary efficacy endpoints in major depressive disorder. Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
• Positive Sentiment: Investors are also reacting to reports that the drug showed “best-case” late-stage results, suggesting meaningful commercial potential if the data hold up in full analysis and regulatory discussions. Definium’s LSD-based pill reduces depression symptoms in late-stage trial
• Neutral Sentiment: The company said it will host a webcast to discuss the results, which could provide more detail on efficacy, safety, and next steps for DT120. Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
• Negative Sentiment: Definium also announced a proposed $500 million public offering, which could dilute existing shareholders even as the stock benefits from the trial win. Definium Therapeutics, Inc. Announces Proposed Public Offering

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.